Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Careers
Investors
News
Contact
PMP22 Reduction by Enhanced Delivery Oligonucleotides Technology is a Promising Approach for Novel CMT1A Therapeutics
Post navigation
Previous:
Nonclinical Data for PGN-EDODM1 Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of DM1
Next:
Results from 15 mg/kg Single Dose PGN-EDODM1 Cohort of FREEDOM-DM1- a Phase 1 Study in People with Myotonic Dystrophy 1 (DM1)
